{
  "ticker": "CC5",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02961706",
  "id": "02961706",
  "pages": 22,
  "price_sensitive": false,
  "date": "20250625",
  "time": "0825",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250625/pdf/06l2h1j7yqygfq.pdf",
  "summary": "**Summary of Clever Culture Systems Ltd (ASX:CC5) Updated Company Presentation (25 June 2025):**  \n\n- **Operational Highlights:**  \n  - 13 APAS\u00ae Independence instruments sold to pharmaceutical customers since March 2024 launch.  \n  - Engaged with **14 of the top 20 global pharmaceutical companies** (by revenue).  \n  - **28 instruments installed globally**, including enterprise customers like AstraZeneca (7 units) and Bristol Myers Squibb (2 units).  \n\n- **Product Expansion:**  \n  - **Contact plates launch (Q1 FY26)** to automate majority of Environmental Monitoring tests, expanding addressable market.  \n  - **Revenue model**: Up to **AUD $1.5M per instrument** (40% upfront Capex, 40% ARR from software, 15% service).  \n\n- **Financial Position (31 March 2025):**  \n  - **Cash**: AUD $2.2M; **Receivables**: AUD $3.6M.  \n  - **Breakeven**: ~11 instrument sales annually (estimated AUD $4.2M cost base).  \n  - **HY25 maiden profit**: AUD $1.1M (driven by AUD $3.8M product sales).  \n\n- **Market Opportunity:**  \n  - **TAM**: AUD $2.8B for aseptic manufacturing microbiology testing.  \n  - **Pipeline**: 40+ qualified leads (~AUD $75M potential upfront sales + AUD $15M p.a. ARR).  \n\n- **Key Catalyst**: Contact plate launch (Q1 FY26) to accelerate sales momentum.  \n\n**No material capital markets actions (e.g., raising, halt) identified.**",
  "usage": {
    "prompt_tokens": 3875,
    "completion_tokens": 361,
    "total_tokens": 4236,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-24T22:37:02.096051"
}